May 10, 2017

BC Platforms bags USD 10 million

BC Platforms has global operations with its headquarters in Switzerland, R&D located in Finland and sales and marketing based in the UK, the US and Canada.
BC Platforms has global operations with its headquarters in Switzerland, R&D located in Finland and sales and marketing based in the UK, the US and Canada.
BC Platforms

Finnish BC Platforms has closed a 10 million-US dollar financing round led by Debiopharm Innovation Fund and Tesi, a Finnish venture capital and private equity company.

BC Platforms’ existing investors also participated in the round.

The company plans to use the funds to launch new technologies integrating complex clinical and genomic data in order to deliver precision medicine and clinical patient benefits, as well as to grow its existing genomic data management software business globally.

BC Platforms provides genomic data management solutions. Its vision is to provide the world’s leading analytics platform for healthcare and industry, with access to over five million subjects’ diverse genomic and clinical data and samples consolidated from a global network of biobanks by 2020. It has created partnerships with over 50 enterprise-level healthcare units and biobanks in 19 countries representing more than two million subjects.

“We are delighted to have been supported by Debiopharm Innovation Fund and Tesi in this new financing round,” says Tero Silvola, CEO at BC Platforms. “This funding will enable us to progress to our next stage of expansion and to launch our new knowledge based solutions for R&D customers worldwide. Debiopharm’s experience in drug development will provide us with invaluable insight as we launch this major new initiative.”

Looking for more good news? Subscribe to our newsletter

Share: